Break-through Infection Following Mpox vaccinatIon

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-12

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the protection of smallpox preexposure vaccination against infection with mpox in real-world individuals with risk factors for mpox.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM

NCT05629299

Monkeypox

UNKNOWN NA

Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts

NCT07267390

Mpox (Monkeypox)

RECRUITING

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

NCT00121849

Cutaneous Leishmaniasis

COMPLETED PHASE1

Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania

NCT00513669

Falciparum Malaria

COMPLETED PHASE1

Reproducibility of Malaria Challenge in Healthy Volunteers

NCT01058226

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Target Trial Emulation study that tries to emulate the sequential specification of a target trial will be conducted measuring and controlling confounders when there is a common cause of vaccination and outcome event.

Participants will be provided with a Quick response (QR) code to access the RedCap study platform, which will guide them to the enrolment process. If the participant accepts and meets all the inclusion and none of the exclusion criteria, they will be directed to a baseline survey to self-collect sociodemographic data and information regarding risk factors, sexual behaviour, vaccination, and exposure to mpox.

Newly vaccinated participants will be matched 1:1 to unvaccinated controls. The matching will be performed based on the site of recruitment, and self-reported baseline sexual health and practices. Vaccinated and unvaccinated participants will be matched on variables associated with the probability of infection.

Follow-up will include regular surveys every month from the index date (i.e., enrolment date in the unvaccinated group, or vaccination date for the vaccinated group), to collect data on change on risk factors, sexual behaviour in the past month, vaccination status, and exposure to mpox. The participant will be asked to self-report if they develop symptoms suggestive of mpox, and the study platform will direct them to a specific mpox infection survey.

For each participant, follow-up will end at the earliest of the following events: mpox infection, voluntary withdraw, or the end of the study period. A health record review will be conducted to corroborate the diagnosis of new cases and to provide validity to the self-report.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mpox

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unvaccinated

Unvaccinated individuals who have risk factors for mpox infection and do not have a past history of mpox infection

No interventions assigned to this group

Vaccinated

Vaccinated individuals with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) who have risk factors for monkeypox infection and do not have a past history of mpox infection.

Mpox Vaccine

Intervention Type DRUG

Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mpox Vaccine

Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individuals aged 18 years or older.
2. Individuals with general risk factors for mpox infection, as currently defined by the local guidelines for vaccination. These risk factors include at least one of the following items:

* Individual-reported use of HIV pre-exposure prophylaxis (PrEP).
* Individual-reported chemsex practices
* Individual-reported multiple sexual partners.
* Individuals with a history of a sexually transmitted infection (STI) in the past year.
* Individuals living with HIV infection.
3. Signature of informed consent.